The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis

• Eric Pelfrene ,

  * E-mail: eric.pelfrene@ema.europa.eu

  Affiliation Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division, European Medicines Agency (EMA), Amsterdam, The Netherlands

  http://orcid.org/0000-0002-5814-5179

  ⨯
• Martin Harvey Allchurch,

  Affiliation International Affairs Division, European Medicines Agency (EMA), Amsterdam, The Netherlands

  http://orcid.org/0000-0003-1894-5144

  ⨯
• Nsengi Ntamabyaliro,

  Affiliation Clinical Pharmacology Unit, University of Kinshasa, Democratic Republic of the Congo

  ⨯
• Victoria Nambasa,

  Affiliation Uganda National Drug Authority, Kampala, Uganda

  ⨯
• Fátima V. Ventura,

  Affiliation Medicines Evaluation Department, National Authority of Medicines and Health Products (INFARMED), Lisbon, Portugal

  ⨯
• Nithyanandan Nagercoil,

  Affiliation Licensing Division, Medicines and Healthcare products Regulatory Agency (MHRA), London, United Kingdom

  ⨯
• Marco Cavaleri

  Affiliation Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division, European Medicines Agency (EMA), Amsterdam, The Netherlands

  ⨯